<!DOCTYPE html>

<html lang="en">
<head>
<meta charset="utf-8"/>
<title>article226</title>
<style>
        body {
            font-family: Arial, sans-serif;
            margin: 0;
            padding: 0;
            background-color: #f3f3f3;
        }
        .container {
            max-width: 800px;
            margin: auto;
            background: #fff;
            padding: 20px;
            box-shadow: 0 0 10px rgba(0, 0, 0, 0.1);
        }
        h1, h2 {
            color: #333;
        }
        p {
            line-height: 1.6;
        }
        a {
            text-decoration: none;
            color: #5a5a5a;
        }
        a:hover {
            color: #000;
        }
    </style>
</head>
<body>
<div class="container"><p><a href="../index.html">Back to Index</a></p><li><a href="https://www.wikijournalclub.org/wiki/AMPLIFY-EXT" style="display:block; margin-bottom:10px;">AMPLIFY-EXT Original</a></li>
<h2><strong>AMPLIFY-EXT</strong></h2>
<div class="container">
<h2><strong></strong></h2>
<div class="container">
<div class="container">
<h2><strong></strong></h2>
<h2><strong></strong></h2>

    "Extended Anticoagulation with Apixaban for Venous Thromboembolism".The New England Journal of Medicine. 2013. 368:699-708.PubMed•Full text•PDF<br/>
<br/>
<h2><strong>Contents</strong></h2><br/>
1Clinical Question<br/>
2Bottom Line<br/>
3Major Points<br/>
4Guidelines<br/>
5Design<br/>
6Population<br/>
6.1Inclusion Criteria<br/>
6.2Exclusion Criteria<br/>
6.3Baseline Characteristics<br/>
7Interventions<br/>
8Outcomes<br/>
8.1Primary Outcomes<br/>
8.2Secondary Outcome<br/>
8.3Additional Analyses<br/>
8.4Adverse Events<br/>
8.5Subgroup Analysis<br/>
9Criticisms<br/>
10Funding<br/>
11Further Reading<br/>
<br/>
<h2><strong>Clinical Question</strong></h2><br/>
For patients with venous thromboembolism who have completed 6 to 12 months of anticoagulation therapy, is extended anticoagulation with apixaban effective in preventing recurrence without increasing the risk of major bleeding?<br/>
<br/>
<h2><strong>Bottom Line</strong></h2><br/>
Extended anticoagulation with apixaban at doses of 2.5 mg or 5 mg twice daily reduced the risk of recurrent venous thromboembolism without increasing the rate of major bleeding.<br/>
<br/>
<h2><strong>Major Points</strong></h2><br/><br/>
<br/>
<h2><strong>Guidelines</strong></h2><br/>
As of the last knowledge update, no guidelines reflecting the results of this trial could be found.<br/>
<br/>
<h2><strong>Design</strong></h2><br/>
- Multicenter, double-blind, randomized, placebo-controlled trial<br/>
- N=2,486<br/>
- Apixaban 2.5mg (n=840)<br/>
- Apixaban 5mg (n=813)<br/>
- Placebo (n=829)<br/>
- Setting: 328 centers in 28 countries<br/>
- Enrollment: 2008-2011<br/>
- Follow-Up: 12 months<br/>
- Analysis: Intention-to-treat<br/>
- Primary Outcome: Composite of symptomatic recurrent venous thromboembolism or death from any cause<br/>
<br/>
<h2><strong>Population</strong></h2><br/>
Inclusion Criteria<br/>
- Age ≥18 years<br/>
- Symptomatic deep-vein thrombosis or pulmonary embolism<br/>
- 6-12 months of anticoagulation therapy completed<br/>
- Clinical equipoise regarding continuation or cessation of anticoagulation<br/>
Exclusion Criteria<br/>
- Contraindication to continued anticoagulant therapy or need for ongoing treatment with other anticoagulants or antiplatelet agents<br/>
- Blood dyscrasias and other exclusions outlined in the study protocol<br/>
Baseline Characteristics<br/>
- Demographic and clinical characteristics well balanced between groups<br/>
<br/>
<h2><strong>Interventions</strong></h2><br/>
- Randomized in a 1:1:1 ratio to receive 2.5 mg or 5 mg of apixaban or placebo, all given twice daily for 12 months<br/>
<br/>
<h2><strong>Outcomes</strong></h2><br/>
Primary Outcomes<br/>
- Composite of symptomatic recurrent venous thromboembolism or death from any cause was significantly lower with apixaban 2.5 mg (3.8%) and 5 mg (4.2%) compared to placebo (11.6%)<br/>
Secondary Outcome<br/>
- Composite of symptomatic recurrent venous thromboembolism or venous thromboembolism-related death; apixaban was superior to placebo<br/>
- Rates of major bleeding were similar across apixaban and placebo groups<br/>
Additional Analyses<br/>
- Assessment of arterial thrombotic events alongside confirmatory results for efficacy and safety<br/>
Adverse Events<br/>
- Similar rates of adverse events across all groups<br/>
Subgroup Analysis<br/>
- Results were consistent among various defined subgroups<br/>
<br/>
<h2><strong>Criticisms</strong></h2><br/>
- More data needed to determine benefit-to-risk profile in specific populations such as older patients, or those with low body weight or renal impairment<br/>
- Limited data on extended treatment beyond 18 to 24 months<br/>
<br/>
<h2><strong>Funding</strong></h2><br/>
Funded by Bristol-Myers Squibb and Pfizer<br/>
<br/>
<h2><strong>Further Reading</strong></h2><br/>
The full text of the article and supplementary materials can be found at NEJM.org
    <p></p>
</div>
</div>
</div>
</div>
</body>
</html>
